Brain Tumor, Primary Clinical Trial
Official title:
Feasibility Study of an MRI-only Workflow: Use of Synthetic CTs Generated From MRI Data for MRI-based Radiotherapy
The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is: - Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.
Status | Not yet recruiting |
Enrollment | 54 |
Est. completion date | August 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent - Patient older than 18 years - Tumor or metastases in the brain - Immobilization with stereotactic mask - Treatment on stereotactic linear accelerator (2.5 mm leafs) equipped with 2D/2D X-ray system Exclusion Criteria: - Metal in the body, metal implants, pacemakers or other patient-specific factors that are a contraindication to an MRI scan - Metal implants, pacemakers or other patient-specific factors associated with increased risk from an MRI scan - Renal insufficiency (eGFR < 60 ml/min), allergy or other patient-specific factors that constitute a contraindication to contrast administration - Renal insufficiency (eGFR < 60 ml/min), allergy or other patient-specific factors associated with an increased risk from contrast administration - Patients who are institutionalized in care facilities, prisons or other supervised facilities. - Patients under guardianship - Non-consenting patients - Pregnant or breastfeeding patients |
Country | Name | City | State |
---|---|---|---|
Germany | Erlangen, Universitätsklinikum Strahlenklinik | Erlangen |
Lead Sponsor | Collaborator |
---|---|
University of Erlangen-Nürnberg Medical School |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients that can successfully be treated in an MRI-only workflow | All criteria have to be met for the MRI-only workflow to be classified as successful:
Verification criteria that will be assessed: Can the sCT be generated and is the sCT clinically utilizable? Are the three rotations needed for CT-MRI registration each = 3°? Can a treatment plan be generated and verified using the sCT? Is the dosimetric difference between sCT and CT based treatment plan in the planning target volume = 3%? Is the dosimetric difference between the sCT and CT based treatment plan in affected organs at risk (receiving > 10% of prescribed dose) = 3%? Are the couch correction parameters during patient positioning in the rotational degrees of freedom = 3°? |
12 month | |
Secondary | Reasons that lead to unfeasibility of an MRI-only workflow | Presence (Yes/No) of individual reasons responsible for the unfeasibility of the MRI-only workflow, as assessed with a predefined checklist. | 12 month | |
Secondary | Dosimetric differences between MRI-only and standard workflow for radiotherapy treatment planning | Paired difference in Dose-volume-histogram parameters (Target coverage, mean, median, near maximum and minimum dose) between MRI-only and standard radiotherapy treatment workflow. | 12 month | |
Secondary | Measurement of intra-MRI patient positional changes | Patient shift (vector magnitude) and rotational errors occuring during the course of MRI acquisition due to patient movement, as assessed by rigid registration of the last acquired MRI sequence in reference to the first sequence. | 12 month | |
Secondary | Organ at risk contouring accuracy on MRI data | Similarity of organ at risk segmentations defined in MRI compared to reference segmentations defined in CT as assessed by the volumetric and surface Dice score, as well as mean surface and Hausdorff distances. | 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
Completed |
NCT03323450 -
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
|
N/A | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Completed |
NCT02599142 -
Comparing Immobilisation Shells in Cranial Radiotherapy
|
N/A | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Recruiting |
NCT06282562 -
FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
|
N/A | |
Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Completed |
NCT04365647 -
Intra-operative Variation in Size of Brain Tumors After Craniotomy
|
||
Not yet recruiting |
NCT06185686 -
Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
|
||
Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
Active, not recruiting |
NCT02006407 -
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
|
N/A | |
Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Recruiting |
NCT05775458 -
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
|
||
Terminated |
NCT04901806 -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03373487 -
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
|
N/A | |
Recruiting |
NCT05254197 -
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
|
||
Recruiting |
NCT05092802 -
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
|
Phase 2 |